AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Howard Hughes Medical Institute · Oregon Health & Science University · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,243
total citations
- FWCI
- 31.51
- Percentile
- 100%
- References
- 31
Citations per year
Authors
28- TOThomas O’HareCorresponding
Howard Hughes Medical Institute, Oregon Health & Science University
- WCWilliam C. Shakespeare
Ariadne Diagnostics (United States)
- XZXiaotian Zhu
Ariadne Diagnostics (United States)
- CAChristopher A. Eide
Howard Hughes Medical Institute, Oregon Health & Science University
- VMVictor M. Rivera
Ariadne Diagnostics (United States)
Topics & keywords
Topics
Keywords
- Myeloid leukemia
- Mutant
- Mutation
- Cancer research
- ABL
- breakpoint cluster region
- Myeloid
- Biology
No related works found for this paper.